Loading
A phase 2 trial of Temozolomide, Silevertinib in brain and spinal cord tumours, run by Black Diamond Therapeutics, Inc., now recruiting.
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII is a phase 2 interventional study registered as NCT07326566 by Black Diamond Therapeutics, Inc., with 162 participants planned, started 2026-05-05 and due to reach its primary completion in 2028-11. Interventions recorded: silevertinib in combination with temozolomide, temozolomide (TMZ). Conditions listed: Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM). No results are recorded here; the registry entry is the source.
Shares Silevertinib, Black Diamond Therapeutics.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy.
Shares Brain and spinal cord tumours (all types), Temozolomide, Cytotoxic chemotherapy.